or Try an Advanced Search...

    Diabetic Nephropathy Stocks List

    Symbol Grade Name % Change
    BMY F Bristol-Myers Squibb Company -0.68
    AMPE F Ampio Pharmaceuticals, Inc. 9.23
    XRTX F XORTX Therapeutics Inc. -0.95
    ZVSA F ZyVersa Therapeutics, Inc. 7.61
    CYCN D Cyclerion Therapeutics, Inc. 28.70
    LABP B Landos Biopharma, Inc. 0.00
    MESO B Mesoblast Limited -0.14
    INCY B Incyte Corporation -0.93
    View As Page of Charts
    Related Industries: Biotechnology Data Storage Drug Manufacturers - Major
    Related Stock Lists: Biopharmaceutical Kidney Disease Medicine Organ Systems Rheumatoid Arthritis Autoimmune Disease Diabetes Heart Failure Inflammation Inflammatory Conditions Kidney Life Sciences S&P 500 Abdominal Pain Adult Stem Cell Alport Syndrome Antioxidant Atrial Fibrillation Autosomal Dominant Polycystic Kidney Disease Back Pain

    Related ETFs - A few ETFs which own one or more of the above listed Diabetic Nephropathy stocks.

    Symbol Grade Name Weight
    FTXH B First Trust Nasdaq Pharmaceuticals ETF 6.93
    PBE B PowerShares Dynamic Biotech & Genome 5.09
    MEDX B Horizon Kinetics Medical ETF 4.29
    WBIY D WBI Power Factor High Dividend ETF 4.04
    IDNA B iShares Genomics Immunology and Healthcare ETF 3.77
    View all Diabetic Nephropathy ETFs...
    Compare ETFs
    Compare FTXH to MEDX Compare MEDX to IDNA Compare PBE to MEDX

        Diabetic Nephropathy Stocks Recent News

        Date Stock Title
        Jun 14 BMY EU to require additional cancer risk labeling on CAR T therapies
        Jun 14 INCY Insider Sale: EVP & General Manager US Barry Flannelly Sells 19,164 Shares of Incyte Corp (INCY)
        Jun 14 BMY Bristol Myers (BMY) Gets FDA Nod for Label Expansion of Augtyro
        Jun 13 BMY Bristol Myers gets FDA approval for Autyro for NTRK-positive cancers
        Jun 13 BMY U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors
        Jun 13 BMY Bristol-Myers Squibb: Move Investing Time Horizon To 2025, At Least
        Jun 13 INCY Incyte Announces Final Results of Tender Offer
        Jun 11 BMY Bristol Myers Squibb (BMY) Beats Stock Market Upswing: What Investors Need to Know
        Jun 11 BMY Bristol-Myers Squibb: Could This Be A Value Trap? (Technical Analysis)
        Jun 11 BMY Bristol-Myers Squibb Company (BMY) Goldman Sachs 45th Annual Global Healthcare Conference
        Jun 11 INCY Incyte tenders ~29.8M shares at $60.00 per share
        Jun 11 INCY Incyte Announces Preliminary Results of Tender Offer
        Jun 9 BMY Bristol Myers: Quality Fundamentals Suppressed By Interest Rates
        Related Industries: Biotechnology Data Storage Drug Manufacturers - Major
        Related Stock Lists: Biopharmaceutical Kidney Disease Medicine Organ Systems Rheumatoid Arthritis Autoimmune Disease Diabetes Heart Failure Inflammation Inflammatory Conditions Kidney Life Sciences S&P 500 Abdominal Pain Adult Stem Cell Alport Syndrome Antioxidant Atrial Fibrillation Autosomal Dominant Polycystic Kidney Disease Back Pain
        Diabetic Nephropathy

        Diabetic nephropathy is a type of kidney disease that is caused by damage to the blood vessels in the kidneys due to diabetes. It is a serious complication of diabetes and can lead to kidney failure. Symptoms of diabetic nephropathy include high blood pressure, swelling in the legs and feet, and protein in the urine. Treatment for diabetic nephropathy includes controlling blood sugar levels, taking medications to reduce blood pressure, and following a healthy diet.

        Browse All Tags